Review in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Afshana QuadiriLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0000-0003-0212-5854
Yassir LekbachLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.
Elhoucine ElfatimiLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.
Swayam PrakashLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0000-0003-3986-890X
Hawa VahedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0000-0002-5753-5378
Sweta KaranLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.
Azizur RehmanLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.
Sarah Xue Le NgLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0009-0007-0187-9132
Chhaya MauryaLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0009-0009-0188-0285
Reilly ChowLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, Gavin Herbert Eye Institute, School of Medicine, University of California, Irvine, CA 92697, USA.ORCID 0000-0001-9468-2521
Funding
A Novel Prime/Pull Therapeutic Vaccine Strategy to Prevent Recurrent Genital HerpesR01AI150091 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI Lbachir BenMohamed · 2020 to 2026
$4.0M
Developing a Multi-epitope Pan-Coronavirus VaccineR01AI158060 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2020 to 2024
$3.7M
Mucosal Chemokines and CD8+ T Cell Immunity to Genital HerpesR01AI143348 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2022
$2.4M
Impact of Immune Checkpoints Blockade on HSV-1 Neuro-PathogenesisR21AI143326 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$464k
LAT-HVEM Interactions Effect HSV-1 Latency/ReactivationR21AI110902 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2015 to 2016
$425k
PROTECTIVE IMMUNITY AGAINST RECURRENT OCULAR HERPES INDUCED WITH SELF-ASSEMBLING PROTEIN NANOPARTICLESR21AI147499 · NIAID · UNIVERSITY OF CALIFORNIA-IRVINE · PI BENMOHAMED, LBACHIR · 2019 to 2020
$399k
A NOVEL SELF-ASSEMBLING PROTEIN NANOPARTICLES-BASED GENITAL HERPES VACCINER41AI138764 · NIAID · SUNOMIX THERAPEUTICS · PI BENMOHAMED, LBACHIR · 2018 to 2018
$236k
A NOVEL IMMUNO-PROTEOMIC APPROACH TO A GENITAL HERPES VACCINER43AI124911 · NIAID · IMMPORT THERAPEUTICS, INC. · PI LIANG, XIAOWU · 2016 to 2016
$225k
NIAID NIH HHS R01 AI143348NIAID NIH HHS R01 AI150091NIAID NIH HHS R01 AI158060NIAID NIH HHS R21 AI110902NIAID NIH HHS R21 AI143326NIAID NIH HHS R21 AI147499NIAID NIH HHS R41 AI138764NIAID NIH HHS R43 AI124911NIH HHS This report was supported by Public Health Service Research grants AI158060, AI150091, AI143348, AI147499, AI143326, AI138764, AI124911, and AI110902 from the National Institutes of Allergy and Infectious Diseases (NIAID) to LBM, and by an unrestricted Re
6 · The paper itself
Abstract
The development of vaccines against many infectious diseases has been a great success of medical science over the last century. However, despite numerous efforts, effective vaccines for herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) remain elusive. Since 1920s, a range of therapeutic vaccine candidates, primarily focusing on neutralizing antibodies, have failed to confer robust and durable protective immunity against recurrent herpes. Recent advances in omics, artificial intelligence, and deep learning have opened new horizons for the rational design of tissue-targeted herpes vaccine strategies for inducing potent and durable HSV-specific CD4
Indexed as
asymptomaticclinical trialsepitopesherpes simplex virus (HSV-1 and HSV-2)immunotherapeuticPPK vaccinessymptomaticvaccines
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Path Towards Effective Long-Lasting Tissue-Targeted Prime/Pull/Keep Herpes Simplex Therapeutic Vaccines. · full record | OpenQuestion